Mylan (MYL) Suit Against FDA Over Hear Drug Dismissed - Bloomberg

December 27, 2012 1:56 PM EST Send to a Friend
Mylan, Inc. (NASDAQ: MYL) saw a little volume move higher following headlines that its suit against the FDA over a generic heart drug was dismissed, according to Bloomberg headlines.

Shares are down 1.4 percent on the session, but off of lows.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

FDA, Litigation

Add Your Comment